Loading market dashboard
China SXT Pharmaceuticals, Inc.
SXTCHealthcareNASDAQCN
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
China SXT Pharmaceuticals (NASDAQ: SXTC - Get Free Report) and Cumberland Pharmaceuticals (NASDAQ: CPIX - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations. Earnings and Valuation This table compares
TAIZHOU, China, March 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the “Company” or “SXTC”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”), today announced that upon the market opening on March 24, 2026, the Company's Class A Ordinary Shares will be traded on The Nasdaq Stock Market under the symbol “SXTC”.
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC - Get Free Report) was the target of a significant drop in short interest during the month of February. As of February 27th, there was short interest totaling 52,570 shares, a drop of 29.1% from the February 12th total of 74,183 shares. Based on an average trading volume of 72,335
